ArriVent BioPharma (AVBP) Net Income towards Common Stockholders (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$43.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 32.72% year-over-year to -$43.3 million; the trailing twelve-month figure through Mar 2026 stood at -$145.2 million (down 13.95% YoY), and the FY2025 full-year result was -$166.3 million, down 106.62% from the prior year.
• Net Income towards Common Stockholders eased to -$43.3 million in Q1 2026, from -$35.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$12.2 million in Q1 2023 to a low of -$64.4 million in Q1 2025.
• A 4-year average of -$27.6 million and a median of -$21.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders sank 269.68% in 2025 and soared 32.72% in 2026, its largest moves.
• Tracing AVBP's Net Income towards Common Stockholders over 4 years: stood at -$21.2 million in 2023, then increased by 2.64% to -$20.6 million in 2024, then plunged by 72.27% to -$35.5 million in 2025, then dropped by 21.88% to -$43.3 million in 2026.
• Business Quant data shows AVBP's Net Income towards Common Stockholders at -$43.3 million in Q1 2026, -$35.5 million in Q4 2025, and -$35.0 million in Q3 2025.